American Society of Hematology

Fig. 3.

$Fig. 3. Immunophenotype of splenocytes from GM-CSF−/−, IL-3−/− doubly deficient mice transplanted with tyrosine kinase fusion oncogenes. / Unfractionated splenocytes stained for mature granulocyte markers Gr-1 and Mac-1 (left panels) and lymphocyte markers CD19 and Thy-1.2 (right panels). “Cntrl” indicates a negative control comprised of spleen cells from a mouse transplanted with a kinase inactive mutant of TEL/TRKC.41 T/P, TEL/PDGFβR; T/J, TEL/JAK2, T/T, TEL/TRKC. Cells were analyzed from mice 3 to 4 weeks following transplant. In all cases, splenic involvement is characterized by pathologic myeloproliferation. Negative control cells demonstrate minimal myeloproliferation and normal lymphocyte populations.$

Immunophenotype of splenocytes from GM-CSF^−/−, IL-3^−/− doubly deficient mice transplanted with tyrosine kinase fusion oncogenes.

Unfractionated splenocytes stained for mature granulocyte markers Gr-1 and Mac-1 (left panels) and lymphocyte markers CD19 and Thy-1.2 (right panels). “Cntrl” indicates a negative control comprised of spleen cells from a mouse transplanted with a kinase inactive mutant of TEL/TRKC.41 T/P, TEL/PDGFβR; T/J, TEL/JAK2, T/T, TEL/TRKC. Cells were analyzed from mice 3 to 4 weeks following transplant. In all cases, splenic involvement is characterized by pathologic myeloproliferation. Negative control cells demonstrate minimal myeloproliferation and normal lymphocyte populations.

This Feature Is Available To Subscribers Only